| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Regeneron's commitment to innovative cancer treatments and pharmaceutical advancements, such as the introduction of Libtayo for CSCC and the Eylea HD for longer dosing intervals, highlights its leadership in addressing pressing healthcare challenges. The focus on long-term treatment efficacy and innovative approaches, particularly with products like Dupixent for chronic inflammatory conditions, demonstrates the company's dedication to improving patient outcomes. These advancements reflect a broader trend of innovation in the pharmaceutical industry that enhances treatment options across various therapeutic areas. However, maintaining a competitive edge amid rapidly evolving market dynamics remains a challenge. |
| The price action of Regeneron Pharmaceuticals (REGN) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.7 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for REGN since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.7, and the negative at -0 on 2025-11-25. The forces of and Valuation Sentiment (-0.1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (3.9) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| REGN | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-25 | 0%(0%) | 0 | 0% | 0.6 | 3.9 | -1 | |||||||
| 2025-11-24 | 0%(0%) | 0 | 0% | 0.6 | 3.4 | -1 | |||||||
| 2025-11-23 | 0%(0%) | 0 | 0% | 0.5 | 3.1 | -1 | |||||||
| 2025-11-22 | 0%(0%) | 0 | 0% | 0.4 | 3.6 | -1 | |||||||
| 2025-11-21 | 0%(0%) | 0 | 0% | 0.4 | 3.6 | -1 | |||||||
| 2025-11-20 | 0%(0%) | 0 | 0% | 0.3 | 2.6 | -1 | |||||||
| 2025-11-19 | 0%(0%) | 0 | 0% | 0.2 | 2.3 | -1 | |||||||
| 2025-11-18 | 0%(0%) | 0 | 0% | 0 | 1.2 | -1 | |||||||
| 2025-11-17 | 0%(0%) | 0 | 0% | 0.1 | 1.6 | -1 | |||||||
| 2025-11-16 | 0%(0%) | 0 | 0% | 0.2 | 2 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-11-25 17:10:13 The partnership between Sanofi and Regeneron plays a crucial role in the development and commercialization of Dupixent, showcasing successful collaboration in the pharmaceutical sector. |
| 2025-11-25 17:10:13 The introduction of Dupixent reflects a growing trend in managing chronic inflammatory diseases with targeted therapies, expanding the treatment landscape. |
| 2025-11-25 17:10:13 Dupixent's approval signifies an innovation in treatment approaches within the pharmaceutical industry, particularly in its ability to address chronic inflammatory conditions. |
| 2025-11-25 17:10:13 The performance of Regeneron stock reflects positive market sentiment following the approval news, indicating investor confidence. |
| 2025-11-25 17:10:13 The approval of Dupixent marks a significant regulatory milestone, highlighting its importance as a targeted therapy for patients with chronic spontaneous urticaria. |